Aurinia Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Aurinia Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AUPH

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada. 

CEO
Kevin C. Tang
CEOKevin C. Tang
Employees
128
Employees128
Headquarters
Edmonton, Alberta
HeadquartersEdmonton, Alberta
Founded
1993
Founded1993
Employees
128
Employees128

AUPH Key Statistics

Market cap
2.26B
Market cap2.26B
Price-Earnings ratio
6.73
Price-Earnings ratio6.73
Dividend yield
Dividend yield
Average volume
1.36M
Average volume1.36M
High today
$16.59
High today$16.59
Low today
$15.60
Low today$15.60
Open price
$16.24
Open price$16.24
Volume
1.55M
Volume1.55M
52 Week high
$19.25
52 Week high$19.25
52 Week low
$10.34
52 Week low$10.34

Stock Snapshot

As of today, Aurinia Pharmaceuticals(AUPH) shares are valued at $15.80. The company's market cap stands at 2.26B, with a P/E ratio of 6.73.

As of 2026-08-08, Aurinia Pharmaceuticals(AUPH) stock has fluctuated between $15.60 and $16.59. The current price stands at $15.80, placing the stock +1.3% above today's low and -4.8% off the high.

Aurinia Pharmaceuticals(AUPH) shares are trading with a volume of 1.55M, against a daily average of 1.36M.

During the past year, Aurinia Pharmaceuticals(AUPH) stock moved between $10.34 at its lowest and $19.25 at its peak.

During the past year, Aurinia Pharmaceuticals(AUPH) stock moved between $10.34 at its lowest and $19.25 at its peak.

AUPH News

Simply Wall St 12h
Aurinia Pharmaceuticals Stock Looks Cheap But Earnings Quality Clouds View - simplywall.st

...

Aurinia Pharmaceuticals Stock Looks Cheap But Earnings Quality Clouds View - simplywall.st
TipRanks 1d
Aurinia Pharmaceuticals price target raised to $16 from $15 at RBC Capital

RBC Capital analyst Douglas Miehm raised the firm’s price target on Aurinia Pharmaceuticals (AUPH) to $16 from $15 and keeps a Sector Perform rating on the shar...

TipRanks 5d
Aurinia Targets Myasthenia Gravis With New Aritinercept Trial, Expanding Its Growth Story

Aurinia Pharmaceuticals (AUPH) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more...

Analyst ratings

50%

of 6 ratings
Buy
50%
Hold
50%
Sell
0%

People also own

Based on the portfolios of people who own AUPH. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.